The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) ...

Oral semaglutide improved glycemic parameters and cardiovascular risk factors for adults with overweight or obesity, with ...

Semaglutide, the drug famously sold under brand names like Ozempic and Wegovy, has boomed in popularity in just a handful of ...

This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...

A novel machine learning gene risk biomarker test successfully predicted patient response to semaglutide treatment after ...

Semaglutide, tirzepatide, and dulaglutide have similar gastrointestinal safety profiles among patients with type 2 diabetes, ...

A new analysis finds that the heart-protecting benefits of semaglutide are largely independent of its weight loss effects.

The FDA has approved Rybelsus® to reduce the risk of MACE in adults with T2DM who are at high risk for these events.

In the recent SOUL trial, the GLP-1 drug reduced the risk of MACE by 14% over 4 years. Next up: a possible obesity indication.

A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and ...

What's better than investing in a stock with a promising outlook? Investing in a beaten-down stock with a promising outlook.